Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 9/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | MMP1 | P03956 | 1/20 | 0.46 |
| ▸ | MMP3 | P08254 | 1/20 | 0.46 |
| ▸ | MMP9 | P14780 | 1/20 | 0.46 |
| ▸ | SIRT2 | Q8IXJ6 | 6/20 | 0.45 |
| ▸ | SIRT1 | Q96EB6 | 3/20 | 0.45 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL830564 | 0.89 | HDAC3 (0.46) | EHMT2MEN1ALDH1A1MAPTMAPK1 | |
| SCHEMBL829897 | 0.88 | HSD17B10 (0.55) | EHMT2ALDH1A1HSD17B10 | |
| SCHEMBL830075 | 0.85 | EHMT2 (0.52) | EHMT2MEN1ALDH1A1MAPTMAPK1 | |
| SCHEMBL828397 | 0.81 | MMP1 (0.56) | EHMT2MMP1MMP3MMP9SIRT2 | |
| SCHEMBL23454666 | 0.81 | MEN1 (0.58) | EHMT2MEN1ALDH1A1MAPTMAPK1 | |
| SCHEMBL26089994 | 0.81 | MEN1 (0.58) | EHMT2MEN1ALDH1A1MAPTMAPK1 | |
| SCHEMBL31092596 | 0.77 | SIRT2 (0.57) | EHMT2MEN1ALDH1A1MAPTMAPK1 | |
| SCHEMBL10064039 | 0.77 | EHMT2 (0.44) | EHMT2MEN1ALDH1A1MAPTMAPK1 | |
| SCHEMBL830026 | 0.77 | EHMT2 (0.46) | EHMT2MEN1ALDH1A1MAPTMAPK1 | |
| Hydrochloric Acid SCHEMBL27138542 | 0.75 | MEN1 (0.58) | EHMT2MEN1ALDH1A1MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178783-A1 | HDAC INHIBITORS | LIXTE BIOTECHNOLOGY, INC. | 2012-07-12 | — | — | US | disclosed |
| US-8143445-B2 | HDAC inhibitors | LIXTE BIOTECHNOLOGY, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| WO-2009045440-A1 | HDAC INHIBITORS | LIXTE BIOTECHNOLOGY HOLDINGS, INC. (US) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178783-A1 | HDAC INHIBITORS | HDAC3, HDAC4, HDAC7 | EHMT2 88/4885MEN1 2353/4885ALDH1A1 2826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.